A bill for an act relating to ensuring the provision of accessible prescription-related measures for persons who are blind, have a visual impairment, or otherwise have print disabilities.
Summary
Senate File 202 requires the Iowa Board of Pharmacy to adopt rules by October 31, 2025, to ensure that people who are blind, visually impaired, or otherwise have print disabilities can access prescription drug labels, bag tags, and medical guides in an accessible format. The bill requires that these accessibility measures be provided at no additional cost, be fully accessible, and be delivered on a timeline comparable to that for non-disabled customers.
The bill also directs the board to solicit input from affected individuals when developing the rules and to align the rules with recommendations from a 2016 U.S. Government Accountability Office report on accessible prescription labels. In addition, the rules must include public notice about the availability of accessible labels, including audio-format options. The board must report to the governor and General Assembly by January 1, 2026, on implementation progress, further recommendations, and projected costs, including any enhanced dispensing fees that might help cover implementation expenses.
Impact
SF 202 would add a new section to Iowa Code chapter 155A governing pharmacy practice and would require the Board of Pharmacy to create enforceable administrative rules on accessible prescription-related information. It would affect pharmacies, pharmacists, and prescription-labeling practices by establishing accessibility obligations for labels, bag tags, and medication guides for people with visual or print disabilities, while also creating a reporting requirement for the board on costs and implementation.
Sentiment
The available context suggests generally supportive or noncontroversial treatment of the bill, with no recorded votes or committee testimony indicating organized opposition. The measure appears framed as a disability-access and consumer-safety bill, which typically draws favorable sentiment because it improves equal access to essential medication information. The subcommittee assignment indicates the bill was under consideration, but the record provided does not show debate or amendments.
Contention
The main potential point of contention is cost and implementation burden. The bill explicitly requires accessible materials at no additional cost to the patient, while also asking the board to report projected costs and possible enhanced dispensing fees to offset provider expenses. That suggests pharmacies, the board, or budget-minded legislators could focus on who pays for the accessibility infrastructure and whether the timeline is feasible. Another possible issue is how the board defines and enforces “fully accessible” formats across different disability needs.
A bill for an act relating to the provision of accessible prescription-related measures for persons who are blind, have a visual impairment, or other print disability.(See HF 2585.)
A bill for an act relating to the provision of accessible prescription-related measures for persons who are blind, have a visual impairment, or other print disability. (Formerly HF 2033.) Effective date: 07/01/2026.
Provides for eligibility for medical assistance for personal care services for persons with traumatic brain injury, developmental disability, cognitive impairments, blindness or visual impairment.
Establishing the blind information access act to require the state library to provide on-demand information access services to persons who are blind, visually impaired, deafblind or print disabled.
Establishing the blind information access act to require the state library to provide on-demand information access services to persons who are blind, visually impaired, deafblind or print disabled.
Prohibits pre-approval or precertification of medical tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.
Prohibits pre-approval or precertification of medical tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.
Prohibits pre-approval or precertification of cancer treatments, tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.